Galectin-9 expression on tumour-associated immune cells is associated with favourable clinicopathological features and better outcomes in oral squamous cell carcinoma.

ABSTRACT:

Introduction

Galectin-9, a β-galactoside-binding protein, might be a potential target in cancer personalized therapy, but contradicting data exist regarding its prognostic significance in malignancy. Previous studies showed low or absent expression of galectin-9 on tumour cells of oral squamous cell carcinoma (OSCC); thus, we aimed to assess the prognostic impact of its expression on tumour-associated immune cells (TAICs).

Material and methods

A retrospective analysis was conducted on 62 patients with OSCC. Tissue microarrays were constructed with chemo- and radiotherapy-naïve tissue samples and stained with anti-galectin-9 antibody. Cytoplasmic reactions in TAICs were counted as positive, and the percentage of galectin-9-positive cells was calculated.

Results

The exp

SUBMITTER: Peksa R 

PROVIDER: S-EPMC10230243 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature